Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)
2026 · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 · Project source
What this source contributed
Records in this release that cite this source. A record can cite several sources.
Results
Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.
Claims
Statements this source supports, each with where in the source it was checked.
- Ladon report: access: Access No model weights, code repository or model licence is published with the report. As checked on 2026-11-15, the GitHub organisation blankbio lists 0 public repositories and the Hugging Face organisation BlankBio lists 0 models. The report's conclusion (page 43) and the announcement invite readers to contact Blank Bio to use the model. Access terms are unresolved; contact the provider. (Page 43, Conclusion, last sentence; Zenodo record Rights field)
- Ladon report: adaptation description conflict: Adaptation description conflict The announcement says 'We fine-tune Ladon on academic immunotherapy cohorts' and that Ladon 'significantly outperforms all baselines'. The report describes supervised mid-training with academic response labels followed by a frozen encoder, PCA and TabICL, and its tests are one-sided and unadjusted (Introducing Ladon, section 'Ladon Predicts Response in Held-Out Clinical Trials'; report pages 11, 15 and 16)
- Ladon report: all gene direction accuracy: All gene direction accuracy At the cutoff including all 9,207 expressed multi-isoform genes, Ladon's direction accuracy is 56% against 53% for direct quantification; the text does not say which of the two contrasts these values belong to (Page 27, sentence 'Ladon nevertheless stayed ahead at every cutoff down to all 9,207 expressed multi-isoform genes (56% compared with 53%)')
- Ladon report: analysis design: Analysis design A benefit head on frozen Ladon embeddings estimates how the treatment-minus-control difference in 12-month PFS varies with molecular features (R-learning, Nie and Wager 2021), after a Ladon-derived score regresses out prognosis in both arms. Source trials: IMmotion150, IMmotion151, IMbrave150, OAK and IMpower133; five-fold cross-fitting with censoring-weighted logistic regression; ridge penalties 10^-4 to 10^3 chosen by leave-one-source-trial-out R-loss. Applied to POPLAR (atezolizumab against docetaxel) (Page 18 and page 22, Methods 'Benefit learning and target evaluation')
- Ladon report: architecture: Architecture 3-billion-parameter transformer encoder-decoder (Page 2, 'Introducing Ladon', first sentence)
- Ladon report: checkpoint identity: Checkpoint identity No checkpoint, model size per experiment or version is named. Figures 20 and 21 compare several model sizes and training steps, but are images with no values in the text layer (Pages 41 to 43, Figures 20 and 21 and Methods 'Reconstruction loss' and 'Clinical benchmark')
- Ladon report: cohort description: Cohort description The announcement calls ARTEMIS and PBCP 'two additional trials'; the report treats the four external sets as cohorts from the Sammut et al. (2022) release and GEO GSE207248, with 35, 13, 18 and 22 patients (Introducing Ladon, section 'Ladon Recovers Cell Composition Signal'; report Figure 18 and page 40)
- Ladon report: comparator gaps printed: Comparator gaps printed The comparator panel of Figure 8 prints 12-month high-low gaps of -2.0 percentage points (atezolizumab) and -2.6 percentage points (docetaxel) for its default selection. The panel header lists PD-L1 mRNA, AP/T, Plasma-cell and TLS3 as toggles and the PDF does not mark which is selected; values for the other three comparators are not printed (Figure 8 (page 19), comparator panel)
- Ladon report: development setting: Development setting IMPRES was developed on melanoma immunotherapy cohorts; these trials are outside that development setting (Web Figure 6 page, DATA master.panel_f.rows, row 'IMPRES', field note)
- Ladon report: development setting: Development setting TIDE was developed on melanoma anti-PD-1 / CTLA-4 cohorts; these trials are outside that development setting. The score is sign-reversed so higher values indicate expected response (Web Figure 6 page, DATA master.panel_f.rows, row 'TIDE', field note)
- Ladon report: figure symbol: Figure symbol In Figure 2 the rows 'Differential gene expression' and 'Hallmark GSEA' carry a double dagger (‡) that the PDF does not explain; it applies to all three panels (Figure 2 (page 6), row labels)
- Ladon report: five gene comparison: Five gene comparison In the five-gene analysis (CD44, INSR, KRAS, MKNK2, TPM1 in the five cancer types where at least four are eligible) Ladon exceeded the cohort-trained baseline in all 21 gene and cancer-type combinations; Figure 12b prints no values (Page 24 prose; Figure 12b (page 25))
- Ladon report: held out protection: Held out protection Pretraining excluded the TCGA cohorts and included the ENCODE4 and blood bulk reference libraries; Ladon received gene-level expression only (Page 28, Methods 'Model input')
- Ladon report: held out protection: Held out protection A random subset of single-cell studies contributed no synthetic bulks to post-training; these held-out studies included the single-cell study paired with the PBMC test bulks (Page 38, Methods 'Ladon post-training')
- Ladon report: held out protection: Held out protection TCGA and CPTAC outcome labels are excluded from Ladon's encoder supervision and validation monitoring; the mid-trained encoder is trained on survival outcomes from other cohorts (Page 11, Methods 'Transfer between TCGA and CPTAC')
- Ladon report: imbrave150 handling: Imbrave150 handling IMbrave150 has no patient-specific clinical covariates; its clinical-only hazard ratio is not estimable, the clinical-only summaries cover five OS and two PFS trials, and the combined predictor uses Ladon alone for IMbrave150 (Pages 13 and 14, Methods 'Survival in held-out trials')
- Ladon report: in sample trial: In sample trial The T-effector signature was derived on POPLAR, so its POPLAR result is in-sample (Web Figure 6 page, DATA master.panel_f.rows, row 'T-effector / IFN-γ', field note)
- Ladon report: ladon higher share: Ladon higher share Ladon's Pearson r is higher than the cohort-trained baseline's in 95.1% of the 14,526 gene and cancer-type combinations, and higher than the linear model on public data and the nearest public samples in 99.7% each (Figure 12a (page 25), 'Ladon higher in' labels)
- Ladon report: marker association counts: Marker association counts Prose: of 304 marker-PFS associations significant before adjustment for Ladon prognosis, 24 remained significant (Benjamini-Hochberg within trial, arm and condition over 550 markers). Figure 7 prints '106 significant' and '0 retained' for its default trial selection; its toggle lists POPLAR, OAK and IMmotion151, while the Methods analyse four trials including IMmotion150; its caption says '550 total' although only markers significant before adjustment are displayed (Page 17 prose; Figure 7 (page 17) and caption; page 20, Methods 'Association models and endpoints')
- Ladon report: median survival split: Median survival split Splitting OAK at the median predicted risk of Ladon + clinical covariates gives median overall survival of 7.9 months in the higher-risk half (n = 349) and 15.5 months in the lower-risk half (n = 350); dashed predicted curves are calibrated using OAK outcomes (Page 7 prose; Figure 4 (page 8) and caption)
- Ladon report: poplar 12 month pfs gap: Poplar 12 month pfs gap Ladon score in POPLAR: 12-month PFS high-low gap 22.1 percentage points in the atezolizumab arm and 1.3 percentage points in the docetaxel arm; 28% against 6% progression-free at 12 months on atezolizumab, 14% against 13% on docetaxel. Patients at risk at month 0: atezolizumab high 43, low 52; docetaxel high 53, low 44 (Figure 8 (page 18), panel 'Ladon + TCGA' headers and at-risk tables; page 18 prose)
- Ladon report: pretraining objective: Pretraining objective Pretrained with masked token reconstruction on isoform-level sequences of millions of bulk RNA-seq samples; self-supervised, so unlabelled samples are used (Page 2, 'Introducing Ladon')
- Ladon report: printed results: Printed results No ClinBench score is printed: Figures 20 and 21 are images, the text layer carries no values, and the task list is not published (Pages 41 and 42, Figures 20 and 21)
- Ladon report: reference data parity: Reference data parity Ladon's in-context examples are 1,419 patients from 33 academic cohorts plus patients from the other trials, and its encoder was mid-trained with response labels from academic cohorts; the gene-expression (gene TPM) baseline uses academic cohorts alone as context. BulkRNABert, BulkFormer and BMRetriever 'use the same PCA and TabICL procedure as Ladon'; whether their context includes the other trials is not stated explicitly, nor which context the DGE signature is fitted in (Pages 15 and 16, Methods 'Immunotherapy response')
- Ladon report: response stratification: Response stratification Figure 9 shows objective response rates in high- and low-score groups of the POPLAR atezolizumab arm (87 of 95 patients with evaluable response) but prints no rate values (Figure 9 (page 20) and caption)
Models, benchmarks and other records
Models (4)
Methods (22)
- ABIS
- BayesPrism (single-cell PBMC references)
- CIBERSORT reimplementation (Ladon report)
- Cohort mean isoform split
- Cohort-trained isoform ridge baseline (Ladon report)
- Differential gene expression signature (Ladon report)
- DWLS reimplementation (Ladon report)
- EPIC (BRef reference)
- Gene TPM features with academic-only context (Ladon report)
- Hallmark GSEA pathway signature (Ladon report)
- HER2 expression (ERBB2 mRNA)
- IMPRES
- Isoform quantification from pooled 10x reads (kallisto)
- Isoform TPM features (Ladon report)
- MammaPrint expression surrogate (genefu gene70)
- Nearest public samples isoform baseline (Ladon report)
- Oncotype DX expression surrogate (genefu oncotypedx)
- Organ-average isoform lookup
- PD-L1 mRNA (CD274 expression)
- Public-reference ridge isoform baseline (Ladon report)
- T-effector / IFN-gamma signature
- TIDE
Configurations (12)
- BulkFormer 147M (Ladon report comparator)
- BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)
- Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)
- Ladon + clinical covariates, concatenated embeddings, ridge Cox (TCGA/CPTAC transfer)
- Ladon + clinical covariates, summed standardised risk scores (held-out trials)
- Ladon deconvolution composition + L2 logistic regression (breast cancer pCR)
- Ladon, composition post-trained, PCA 64 + TabICL regressors (PBMC deconvolution)
- Ladon, pretrained encoder, isoform percentages imputed from gene-level counts
- Ladon, response mid-trained, PCA 128 + TabICL v2 (held-out trial response)
- Ladon, ridge Cox fitted on TCGA plus non-trial cohorts and other trials (training-pool study)
- Ladon, survival mid-trained, ridge Cox fitted on one cohort (TCGA/CPTAC transfer)
- Ladon, survival mid-trained, ridge Cox fitted on TCGA and other trials (held-out trials)
Benchmarks (1)
Tasks (6)
- Cell-type deconvolution of bulk RNA-seq with single-cell references
- Immunotherapy response from pretreatment bulk RNA-seq
- Isoform usage recovery from gene-level expression
- Pathological complete response from inferred tumour composition
- Survival prognosis from pretreatment bulk RNA-seq
- Treatment benefit (predictive biomarker) from bulk RNA-seq
Protocols (19)
- Blood single-cell to isoform, direction accuracy for COVID-19 against healthy draws, top 5% of genes
- Blood single-cell to isoform, direction accuracy for day 0 to day 14 change, top 5% of genes
- Breast cancer pCR, ER+/HER2- external cohorts, AUC of a model fitted on TransNEO
- Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO
- ENCODE4 within-donor organ pairs, Pearson r of predicted against measured isoform change
- Held-out trials, immunotherapy response AUROC, equal mean over six trials
- Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
- Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool
- Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
- INSR isoform split in TCGA stomach tumours, mean absolute error
- INSR isoform split in TCGA stomach tumours, Pearson r
- Isoform variation in eight held-out TCGA cancer types, median Pearson r over gene and cancer-type pairs
- OAK overall survival, Uno C-index of a predictor fitted on other cohorts
- PBMC deconvolution, pairwise ordering accuracy, mean over five lineages
- PBMC deconvolution, Pearson r of inferred against measured shares, mean over five lineages
- PBMC deconvolution, per-lineage Pearson r of inferred against measured shares
- Survival transfer CPTAC to TCGA, mean Uno C-index over six cancers
- Survival transfer TCGA and CPTAC, pan-cancer Uno C-index, mean of two directions
- Survival transfer TCGA to CPTAC, mean Uno C-index over six cancers
Datasets (7)
- Clinical trial pretreatment RNA-seq cohorts (Ladon report)
- CPTAC bulk RNA-seq with clinical outcomes (as used in the Ladon report)
- DFCI inflammatory breast cancer pretreatment biopsies (GSE207248)
- ENCODE4 paired bulk and single-nucleus RNA-seq of donor organs
- Giroux et al. 2022 COVID-19 blood cohort, paired bulk and single-cell RNA-seq
- Sammut et al. 2022 breast cancer neoadjuvant cohorts (TransNEO, ARTEMIS, PBCP)
- TCGA bulk RNA-seq with clinical outcomes (as used in the Ladon report)
Dataset subsets (16)
- ARTEMIS ER+/HER2- patients (35, 3 pCR)
- CPTAC six-cancer transfer target set (1,128 patients)
- DFCI inflammatory breast cancer HER2+ patients (22, 9 pCR)
- ENCODE4 within-donor organ-pair isoform contrasts (1,402 comparisons)
- Giroux blood draws for isoform direction (35 draws, 17 people)
- Giroux PBMC bulk RNA-seq test set for deconvolution (35 bulks, 17 donors)
- Immunotherapy arms of six held-out trials with evaluable response
- OAK RNA-profiled patients (699)
- PBCP ER+/HER2- patients (13, 3 pCR)
- PBCP HER2+ patients (18, 11 pCR)
- Six held-out trials with overall survival
- TCGA and CPTAC transfer target sets combined (pan-cancer panel)
- TCGA six-cancer transfer target set (2,461 patients)
- TCGA stomach adenocarcinomas with INSR at least 10 TPM (166)
- TCGA tumours of eight held-out cancer types for isoform recovery (1,572)
- Three held-out trials with progression-free survival
Evaluations (93)
- ABIS, PBMC deconvolution, pairwise ordering accuracy
- ABIS, PBMC deconvolution, pearson r
- BayesPrism, PBMC deconvolution, pairwise ordering accuracy
- BayesPrism, PBMC deconvolution, pearson r
- BulkFormer, held-out trials immunotherapy response AUROC
- BulkFormer, held-out trials OS hazard ratio
- BulkFormer, held-out trials PFS hazard ratio
- BulkFormer, survival transfer CPTAC to TCGA, Uno C-index
- BulkFormer, survival transfer pan-cancer, Uno C-index
- BulkFormer, survival transfer TCGA to CPTAC, Uno C-index
- BulkRNABert, held-out trials immunotherapy response AUROC
- BulkRNABert, held-out trials OS hazard ratio
- BulkRNABert, held-out trials PFS hazard ratio
- BulkRNABert, survival transfer CPTAC to TCGA, Uno C-index
- BulkRNABert, survival transfer pan-cancer, Uno C-index
- BulkRNABert, survival transfer TCGA to CPTAC, Uno C-index
- CIBERSORT, PBMC deconvolution per-lineage Pearson r
- CIBERSORT, PBMC deconvolution, pairwise ordering accuracy
- CIBERSORT, PBMC deconvolution, pearson r
- Clinical covariates (BMRetriever), held-out trials immunotherapy response AUROC
- Clinical covariates (BMRetriever), held-out trials OS hazard ratio
- Clinical covariates (BMRetriever), held-out trials PFS hazard ratio
- Clinical covariates (BMRetriever), survival transfer CPTAC to TCGA, Uno C-index
- Clinical covariates (BMRetriever), survival transfer pan-cancer, Uno C-index
- Clinical covariates (BMRetriever), survival transfer TCGA to CPTAC, Uno C-index
Sources (3)
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
31 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Access note Zenodo access_right is open, which covers downloading this PDF only. No model weights, code repository or model licence is published with the report. As checked on 2026-11-15, the GitHub organisation blankbio lists 0 public repositories and the Hugging Face organisation BlankBio lists 0 models. The report's conclusion (page 43) and the announcement invite readers to contact Blank Bio to use the model. Access terms are unresolved; contact the provider. Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Artifact SHA-256 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Code licence None stated. The report links no code, weights or model licence. Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Doi 10.5281/zenodo.24157116 Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Licence Copyright (C) 2026 Blank Bio. All rights reserved. (Zenodo record, Rights field) Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Limitations3 values
| Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Media type application/pdf Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Publication status official_project_source Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Retrieval url https://zenodo.org/api/records/24157116/files/Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf/content Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Retrieved at 2026-11-15T20:29:10Z Source metadata | Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) No field-specific location recorded Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026 | catalogued No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
The Blank Bio technical report introducing Ladon, a bulk RNA-seq foundation model, and its evaluations on survival, immunotherapy response, treatment benefit, isoform recovery and cell composition.
1 source record and release history
- Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Original source · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Technical metadata and extraction receipts
Stable ID: ladon-20261115-source-zenodo-pdf
- areas
- rna-transcriptomes
- contexts
- clinical_research
- access note
- Zenodo access_right is open, which covers downloading this PDF only. No model weights, code repository or model licence is published with the report. As checked on 2026-11-15, the GitHub organisation blankbio lists 0 public repositories and the Hugging Face organisation BlankBio lists 0 models. The report's conclusion (page 43) and the announcement invite readers to contact Blank Bio to use the model. Access terms are unresolved; contact the provider.
- artifact sha256
- 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c
- code licence
- None stated. The report links no code, weights or model licence.
- doi
- 10.5281/zenodo.24157116
- licence
- Copyright (C) 2026 Blank Bio. All rights reserved. (Zenodo record, Rights field)
- limitations
- Company technical report deposited on Zenodo; not peer reviewed.; The PDF is a print of an interactive web page. Per-trial values, p-values and confidence intervals that the web version shows on hover or in collapsed data tables are not printed in the PDF.; All rights reserved: the PDF and its text layer are not archived in this repository.
- media type
- application/pdf
- publication status
- official_project_source
- retrieval url
- https://zenodo.org/api/records/24157116/files/Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf/content
- retrieved at
- 2026-11-15T20:29:10Z
- review
- artifact sha256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c; method: source-hash-verification; automated-source-review; method note: Independent review pass. Each pinned artifact was re-retrieved at review time and its SHA-256 recomputed: the Zenodo PDF matched (and its MD5 matched the Zenodo file checksum), and the three HTML artifacts matched byte for byte, although all three are mutable and the hash describes one retrieval. The PDF text layer regenerated with pdftotext 26.08.0 -layout reproduced the SHA-256 the source record's version_note states, so the text every value was read from is provably derived from the pinned bytes.; note: Artifact re-retrieved at review time; hash matched the source record.; retrieval url: https://zenodo.org/api/records/24157116/files/Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf/content; reviewed at: 2026-11-15T23:30:00Z; reviewer: claude; reviewer note: Claude review agent, independent of the extractor; no human review claimed. Transcription was checked against the pinned sources, which is not reproduction: nothing was rerun and no value was recomputed.
- source locator
- Whole document; title page (page 1) for authors, date and DOI
- url
- https://doi.org/10.5281/zenodo.24157116
- version
- Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
- version note
- Downloaded twice on 2026-11-15 (about 20:22Z and 20:29Z) with identical bytes; the MD5 matches the Zenodo file checksum abc8168cf6059ee806b34ced791434fb. Values were read from a pdftotext 26.08.0 -layout text layer, SHA-256 2f5a65a1e6b9830dd2aa1e0155865462c34a58451a230657f697d110b637bd6d.
- year
- 2026
Related records
- subject: Ladon report: significance testing
- companion of: Introducing Ladon (Blank Bio announcement)
- companion of: Ladon technical report, Figure 6 page (web)
- companion of: Ladon Technical Report (web page)